FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer

The FDA has granted accelerated designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression on an androgen receptor (AR) pathway inhibitor.1 An antibody-drug conjugate (ADC), ARX517 consists of a fully humanized prostate-specific membrane antigen (PSMA) monoclonal antibody that is bound to AS269. …

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer Read More »